Novartis to Pay $422.5M to Settle Off-label Drug Marketing Charges



Novartis Pharmaceuticals Corp. will plead guilty and pay criminal and civil fines totaling $422.5 million to resolve claims that it used off-label marketing to illegally promote the antiepileptic Trileptal and five other drugs, federal prosecutors said Thursday.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below:

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.